FIELD: medicinal virology. SUBSTANCE: vaccine strain A/17 Texas/91/1/3 (H1N1) is obtained by method of genetic reassortation of epidemic virus A/Texas/36/91 (H1N1) with cold-adapted strain A/Leningrad/134/17 (H2N2) - attenuation donor followed by selection in the presence of antiserum to virus A/Leningrad/134/17/57 (H2N2). Infectious activity at reproduction in developing embryos at 32 C for 48 h - 7.0 lg EID 50/0.2 ml, hemagglutinating activity = 1:256. EFFECT: strain indicated above, enhanced effectiveness of vaccine. 1 tbl
Authors
Dates
1997-07-20—Published
1994-09-30—Filed